25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
September 2025 in “Turkish Journal of Dermatology” Oxidative stress may play a role in alopecia areata, but depression and suicide risk are similar to healthy peers.
March 2025 in “Journal of Cosmetic Dermatology” Finasteride use may increase depression and suicide risk, especially at 1 mg, so monitoring is advised.
May 2026 in “Reactions Weekly” Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.
June 2026 in “The Pharmacogenomics Journal” September 2025 in “Therapies” Finasteride use for hair loss may cause depression and suicidal thoughts, requiring careful monitoring.
1 citations
,
March 2023 in “Scientific Reports” Finasteride may increase the risk of suicide or severe self-harm in men with mood disorders but not in the general population.
December 2022 in “JAMA network open” 5α-Reductase inhibitors may increase depression risk but not dementia or suicide.
6 citations
,
January 2020 in “Dermatology” Finasteride may increase suicide risk; more research needed.
April 2022 in “The Journal of Sexual Medicine” Finasteride alone increases suicide risk, but combining it with other treatments reduces this risk.
June 2025 in “Clinical and Experimental Dermatology” Finasteride does not increase the risk of suicide attempts.
December 2025 in “Journal of Cosmetic Dermatology” Finasteride does not increase the risk of depression or suicide.
Participating in Sexual Orientation Change Efforts may increase the risk of suicide for sexual minority individuals.
May 2024 in “European urology focus” Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.
November 2021 in “Evidencia” Young patients using finasteride may have higher risks of anxiety, depression, and suicidal thoughts.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
August 2018 in “Journal of The American Academy of Dermatology” Finasteride use for hair loss is linked to an increased risk of suicidal thoughts and a higher risk of suicide.
August 2018 in “Journal of The American Academy of Dermatology” The conclusion is that finasteride is linked to an increased risk of suicidal thoughts and a higher risk of completed suicide when used for hair loss.
2 citations
,
July 2019 in “Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)” No proven link between isotretinoin and depression.
May 2017 in “Psychiatric news” BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
2 citations
,
November 2021 in “Journal of Clinical Psychopharmacology” Finasteride may affect mood and increase suicidal risk.
September 2025 in “The Journal of Clinical Psychiatry” Finasteride may increase depression and suicide risks, needing better safety checks and informed consent.
June 2025 in “Cermin Dunia Kedokteran” Early detection and prevention of suicide risk in teens is crucial, involving healthcare awareness, family support, and cross-sector collaboration.
30 citations
,
April 2007 in “Dermatologic Clinics” The document concludes that new treatments are needed to better manage acne and reduce side effects related to current therapies.
August 2018 in “Journal of The American Academy of Dermatology” Finasteride, a hair loss drug, is linked to increased suicidal thoughts, particularly when used for hair loss.
December 2025 in “Instituto Politécnico do Porto” Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.
March 2019 in “Reactions Weekly” Finasteride may increase risk of suicidal thoughts and self-harm.
1 citations
,
August 2017 in “The Journal of urology/The journal of urology” 5α-reductase inhibitors may increase the risk of depression and suicidal thoughts.
90 citations
,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.